Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1)

Background Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate atopic dermatitis (AD). Objectives The aim of this study was to evaluate the safety, effectiveness, and pharmacokinetics (PK) of crisaborole in infants aged 3 to 

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of clinical dermatology 2020-04, Vol.21 (2), p.275-284
Hauptverfasser: Schlessinger, Joel, Shepard, Julie S., Gower, Richard, Su, John C., Lynde, Charles, Cha, Amy, Ports, William C., Purohit, Vivek, Takiya, Liza, Werth, John L., Zang, Chuanbo, Vlahos, Bonnie
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate atopic dermatitis (AD). Objectives The aim of this study was to evaluate the safety, effectiveness, and pharmacokinetics (PK) of crisaborole in infants aged 3 to 
ISSN:1175-0561
1179-1888
DOI:10.1007/s40257-020-00510-6